Two-Step Wet Granulation for Moisture-Sensitive Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Moisture-sensitive active pharmaceutical ingredients like Cilazapril degrade rapidly in the presence of water, making it challenging to create stable pharmaceutical compositions, especially when combined with other drugs like Hydrochlorothiazide using traditional wet granulation processes.
Innovation Solution
A two-step wet granulation process where the moisture-sensitive active pharmaceutical ingredient, such as Cilazapril, is first granulated with a binder and processing solvent, followed by the addition of the second drug, Hydrochlorothiazide, to form a stable combined granulate, which is then dried and formulated into tablets with additional excipients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a traditional wet granulation process is used to combine moisture-sensitive drugs with other drugs, then the manufacturing process is simple and efficient, but the stability of the moisture-sensitive drug deteriorates due to rapid degradation in the presence of water
Solution Approach 1:
The wet granulation process is divided into two distinct steps: first, the moisture-sensitive drug is granulated with binder and processing solvent to form a stable wet granulate; second, the second drug is added to the wet granulate. This segmentation prevents direct contact between the moisture-sensitive drug and water during the granulation process, thereby maintaining drug stability while still using an efficient wet granulation method.
Solution Approach 2:
The moisture-sensitive drug is first granulated and formed into a stable wet granulate structure before the second drug is added. This preliminary action creates a protective matrix that prevents water exposure to the moisture-sensitive drug during subsequent processing and storage, resolving the contradiction between manufacturing efficiency and drug stability.
2Stability of the object's composition
If a dry manufacturing process is used for moisture-sensitive drugs, then the stability of the drug is improved by avoiding water exposure, but the ease of manufacture deteriorates due to increased process complexity
Solution Approach 1:
The process is segmented into a first wet granulation step for the moisture-sensitive drug followed by addition of the second drug. This allows the use of wet granulation (which is simpler and more efficient than dry processes) while maintaining stability through the specific sequencing and protective matrix formation.
Solution Approach 2:
The invention changes the temporal parameter of the wet granulation process by performing it in two stages rather than one. The first stage creates a stable wet granulate with controlled moisture content, and the second stage adds the second drug. This parameter change allows wet granulation to be used while maintaining drug stability.
3Stability of the object's composition
If water scavenger compounds are incorporated into the tablet matrix, then the stability of moisture-sensitive drugs is improved, but the device complexity increases due to additional components and process steps
Solution Approach 1:
The invention extracts the water scavenging function from separate compounds and integrates it into the wet granulate structure itself. The wet granulate formed in the first step acts as an intrinsic moisture barrier, eliminating the need for additional water scavenger compounds and simplifying the formulation while maintaining stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method significantly improves the stability of the pharmaceutical composition, reducing the formation of major degradation products like Cilazaprilat to less than 1% by weight, even under high humidity and temperature storage conditions, maintaining the integrity of the active ingredients.
Implementation Method 1
wet granulated with a solution of at least one pharmaceutical excipient in at least one processing solvent
Implementation Method 2
wetting and then drying the composition at an elevated temperature
Implementation Method 3
solution of at least one pharmaceutical excipient in at least one processing solvent
Implementation Method 4
drying the composition at an elevated temperature
Data Source
AI summary
The present invention relates to stable pharmaceutical compositions comprising a combination of a moisture sensitive active pharmaceutical ingredient (drug), in particular an angiotensin converting enzyme (ACE) inhibitor such as Cilazapril, and a second drug, such as Hydrochlorothiazide, as the active ingredients and methods for preparing such stable pharmaceutical compositions.